Fluticasone propionate/salmeterol (Advair Diskus) vs Fluticasone propionate/salmeterol (Advair HFA)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline

Fluticasone propionate/salmeterol (Advair Diskus)

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Partial signal

NCT00920959 · Phase 3 · completed

This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)

Result source: NCT00920959

Fluticasone propionate/salmeterol (Advair HFA)

Marketed by GlaxoSmithKline

Approved in Asthmacombination (ICS + LABA)
Partial signal

NCT00448435 · Phase 3 · completed

The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.

Reported efficacy

Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)

Result source: NCT00448435

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFluticasone propionate/​salmeterol (Advair Diskus)Fluticasone propionate/​salmeterol (Advair HFA)
Severe exacerbations, annualised rate2.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT004523481.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
—Not posted · NCT00646620
ACQ-5, change—Not posted · NCT00920959—Not posted · NCT00646620
OCS dose reduction—Not posted · NCT00920959—Not posted · NCT00646620

Severe exacerbations, annualised rate

Fluticasone propionate/​salmeterol (Advair Diskus)
2.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT00452348
Fluticasone propionate/​salmeterol (Advair HFA)
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699

Trough FEV1, change

Fluticasone propionate/​salmeterol (Advair Diskus)
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

ACQ-5, change

Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

OCS dose reduction

Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Fluticasone propionate/salmeterol (Advair Diskus): 6 of 6 rows · Fluticasone propionate/salmeterol (Advair HFA): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone propionate/​salmeterol (Advair Diskus)
Rows use multiple source trials
Fluticasone propionate/​salmeterol (Advair HFA)
Asthma Symptom Free
absolute value · % of time
27.3 vs 28.6 FP % of time @ 4wk100/50mcg BIDa,b,c
NCT00118716 · Phase 4 · registry result, not featured evidence
37.1 vs 28.5 Fluticasone Propionate % of time @ 52wk250/50 mcg BIDa,b,c
NCT00452699 · Phase 4 · registry result, not featured evidence
FEV1
absolute change · L
0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailyd,e,a,b,f
NCT02301975 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDe,a,b,f
NCT00452699 · Phase 4 · registry result, not featured evidence
Dropout rate
0.2%g
NCT01475721 · Phase 4
show 14 more results
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
7.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—50/100 mcg/dayh
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
0%
NCT00449046 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT01475721 · Phase 4
show 14 more results
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
0.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—50/100 mcg/dayh
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Serious AEs
2.3%g
NCT01475721 · Phase 4
show 14 more results
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
4.4%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0%100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
0%
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%50/100 mcg/dayh
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
0%50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
g
asthma 0.8%
NCT01475721 · Phase 4
show 14 more results
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/31.25/25 mcg
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
250/50 mcg BID
headache 11%
hypertension 6.1%
blood pressure increased 0%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
250/50 mcg BID
headache 12.2%
hypertension 4.9%
blood pressure increased 3.7%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100mcg/50mcg
cough 5%
upper respiratory infection 5%
viral upper respiratory infection 5%
NCT00927758 · Phase 2 · registry result, not featured evidence
headache 5.6% (placebo 5.4%)
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
50/100 mcg/dayh
upper respiratory tract inflammation 13.7%
nasopharyngitis 3.9%
stomatitis 3.9%
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
50/100 mcg/day
upper respiratory tract inflammation 34%
gastroenteritis 14%
nasopharyngitis 14%
NCT00448435 · Phase 3 · Asthma · phase 3
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
asthma 20%
bronchitis 20%
laryngopharyngitis 20%
NCT00449046 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 4 weeks versus 52 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 3 versus Phase 4.
  6. fAssessment timepoints differ: 24 weeks versus 52 weeks.
  7. gPopulation comparability has not been reviewed for 8 of these studies.
  8. hPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone propionate/salmeterol (Advair Diskus)

Asthma Exacerbation Occurrence 8.2% (n=5834) vs 10.2% (n=5845) Fluticasone Propionate @ 26wk
event count · % of participants
NCT01475721 · Phase 4 · converted to % from 480 Participants as posted
FEV1 Trough 0.16 vs 0.12 FP DISKUS L @ 52wk250/50 mcg BID
absolute change · L
NCT00452348 · Phase 4 · registry result, not featured evidence
show 5 more results
0.12 vs 0.024 FF/VI L @ 24wk100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.157 vs 0.024 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.134 vs 0.024 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.168 vs 0.024 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.081 vs -0.083 placebo L @ 0.14wk
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
Morning PEF 27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
absolute change · L
NCT00452348 · Phase 4 · registry result, not featured evidence
show 2 more results
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 Max Fall -9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BID
absolute value · percentage points
NCT00118716 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence
Evening PEF 10.8 vs 7.6 FP L/min @ 4wk100/50mcg BID
absolute change · L/min
NCT00118716 · Phase 4 · registry result, not featured evidence
Rescue-free 59.4 vs 54.7 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
PAQLQ 0.49 vs 0.52 FP score @ 2wk100/50mcg BID
absolute change · score
Overall score Week 2
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

Fluticasone propionate/salmeterol (Advair HFA)

Morning PEF Change L/Min 14.3 vs 17.1 SLM + FP L50/100 mcg/day
absolute change · L
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 5.38% (n=48) vs 6.73% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 5.01% (n=48) vs 6.46% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 16.3 vs 15.8 SLM + FP L/min50/100 mcg/day
absolute change · L/min
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation 0.06% (n=48) vs -0.08% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Symptom-Free Nights and 91.7% (n=48) vs 81.3% (n=48) SLM + FP @ 4wk50/100 mcg/day
absolute value · percentage points
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Rescue Medication-Free Nights 93.8% (n=48) vs 87.5% (n=48) SLM + FP @ 4wk50/100 mcg/day
responder rate · % of participants
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Change L/Min 3 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 1.46% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 1.29% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 2.7 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation -0.37% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair Diskus)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape